

Munich, 02. May 2017

press release

terrapiasma medical successfully completes financing

In March 2017, the Munich-based medical technology company terrapiasma medical GmbH – founded by terrapiasma GmbH and Dynamify GmbH – successfully completed the first round of major financing (seed). A number of very experienced private investors are funding the company with a seven-figure Euro amount. The money will enable the company to develop and establish market approval of the plasma care – a mobile, battery-powered medical device for in- and outpatient treatment of chronic and acute wounds using cold plasma, destroying fungi and multi-resistant bacteria.

Bacteria – especially multi-resistant germs – are one of the greatest problems in difficult-to-heal chronic and acute wounds. The terrapiasma medical device aims to optimize the wound treatment process carried out by medical professionals and to reduce the pain suffered by the patients and increase their quality of life.

In order to achieve this vision, terrapiasma medical is developing a mobile, battery-powered medical device for inpatient and outpatient treatment of chronic and acute wounds, which kills even multi-resistant bacteria by applying cold plasma. Plasma is often referred to as a fourth aggregate state (in addition to solid, liquid and gaseous) and describes a particle mixture whose actual components are partially charged components.

In a clinical study led by the City Clinic Schwabing (Munich Municipal Hospital Group), Germany, and the University Hospital Regensburg, Germany, in cooperation with Prof Dr Gregor Morfill and PD Dr Julia Zimmermann, 300 patients were treated with cold plasma. The highly efficient bactericidal effect of cold plasmas in chronic and acute wounds was proven with great success.

The investor group possesses great expertise in this branch and is led by Gerd Reimann-Dubbers, Ali Alghanim, Rainer Baule and Fabian von Kuenheim. They are based in the Business Angels Regions of Stuttgart (BARS) and Munich. "We are thrilled to have such an experienced and exceptionally well-connected investor group financially supporting our vision of an innovative wound treatment product based on cold plasma", says Jens Kirsch, Managing Director of terrapiasma medical.

Within the framework of this financing round an advisory board was established consisting of Mr Baule and Mr von Kuenheim. The managing directors are Julia Zimmermann and Jens Kirsch. Rainer Baule substantiates the investment saying, "We are very optimistic that due to the extensive experience of the management and the existing clinical data an innovative medical product can be approved for wound treatment within a reasonable period of time."

For further information, please visit www.terrapiasma-medical.com

Contact:

Jens Kirsch
Lichtenbergstraße 8
85748 Garching near Munich
Germany
Office +49 (0)89 7167 7957-0
Fax +49 (0)89 7167 7957-9
Email: jens.kirsch@terrapiasma-medical.com

Learn more about Kuenheim Familiaris

Kuenheim Familiaris GmbH is the private investment establishment of the family of Fabian von Kuenheim. Fabian von Kuenheim was co-founder, largest shareholder and chairman of the management board of Magirus AG, which he successfully sold to Avnet Inc. Through Kuenheim Familiaris GmbH Fabian v. Kuenheim places investments in high-tech companies active in the areas of autonomous driving, mobility and integrated mobile systems, life science, industry 4.0, IT-infrastructure Cloud computing as well as in companies operating at the interfaces of these technologies. Preferable Fabian v. Kuenheim operates within a scope of syndicated investor groups from his network.

Contact:

Kuenheim Familiaris GmbH

Eichwiesenring 9 | D- 70567 Stuttgart | Germany

Office: +49-(711)-720770-12 | Fax +49-(711)-720770-10

Email: info@kuenheim.com